Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180899-06
Application #
9627747
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-23
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Public Health Institute
Department
Type
DUNS #
128663390
City
Oakland
State
CA
Country
United States
Zip Code
94607
Malempati, Suman; Weigel, Brenda J; Chi, Yueh-Yun et al. (2018) The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer :
Hawkins, Douglas S; Chi, Yueh-Yun; Anderson, James R et al. (2018) Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol 36:2770-2777
Cajaiba, Mariana M; Dyer, Lisa M; Geller, James I et al. (2018) The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer 124:3381-3389
Roberts, Kathryn G; Reshmi, Shalini C; Harvey, Richard C et al. (2018) Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. Blood 132:815-824
McCarten, Kathleen M; Metzger, Monika L; Drachtman, Richard A et al. (2018) Significance of pleural effusion at diagnosis in pediatric Hodgkin lymphoma: a report from Children's Oncology Group protocol AHOD0031. Pediatr Radiol 48:1736-1744
Rajbhandari, Presha; Lopez, Gonzalo; Capdevila, Claudia et al. (2018) Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discov 8:582-599
Bride, Karen L; Vincent, Tiffaney L; Im, Soo-Yeon et al. (2018) Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 131:995-999
DiNofia, Amanda M; Seif, Alix E; Devidas, Meenakshi et al. (2018) Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. Cancer Med 7:3-12
Zhang, Xinrui; Muller, Keith E; Goodenow, Maureen M et al. (2018) Internal pilot design for balanced repeated measures. Stat Med 37:375-389
Noort, Sanne; Zimmermann, Martin; Reinhardt, Dirk et al. (2018) Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. Blood 132:1584-1592

Showing the most recent 10 out of 317 publications